Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study.
Lapucci C, Frau J, Cocco E, Coghe G, Petracca M, Lanzillo R, Brescia Morra V, Nicoletti CG, Landi D, Marfia G, Vercellino M, Cavalla P, Bianco A, Mirabella M, Torri Clerici V, Tomas E, Ferrò MT, Grossi P, Nozzolillo A, Moiola L, Zaffaroni M, Ronzoni M, Pinardi F, Novi G, Cellerino M, Uccelli A, Inglese M. Lapucci C, et al. Among authors: mirabella m. Mult Scler. 2024 Aug;30(9):1151-1162. doi: 10.1177/13524585241266509. Epub 2024 Aug 14. Mult Scler. 2024. PMID: 39143825
The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing-remitting multiple sclerosis.
Frisullo G, Mirabella M, Angelucci F, Caggiula M, Morosetti R, Sancricca C, Patanella AK, Nociti V, Iorio R, Bianco A, Tomassini V, Pozzilli C, Tonali PA, Matarese G, Batocchi AP. Frisullo G, et al. Among authors: mirabella m. J Neuroimmunol. 2007 Dec;192(1-2):174-83. doi: 10.1016/j.jneuroim.2007.08.008. Epub 2007 Sep 29. J Neuroimmunol. 2007. PMID: 17904647
Acyclovir-related kidney injury during alemtuzumab infusion.
Bianco A, Gambaro G, Rossini PM, Mirabella M. Bianco A, et al. Among authors: mirabella m. J Neurol. 2015 Jul;262(7):1772-4. doi: 10.1007/s00415-015-7786-4. Epub 2015 Jun 3. J Neurol. 2015. PMID: 26037015 No abstract available.
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.
Patti F, Messina S, Solaro C, Amato MP, Bergamaschi R, Bonavita S, Bruno Bossio R, Brescia Morra V, Costantino GF, Cavalla P, Centonze D, Comi G, Cottone S, Danni M, Francia A, Gajofatto A, Gasperini C, Ghezzi A, Iudice A, Lus G, Maniscalco GT, Marrosu MG, Matta M, Mirabella M, Montanari E, Pozzilli C, Rovaris M, Sessa E, Spitaleri D, Trojano M, Valentino P, Zappia M; SA.FE. study group. Patti F, et al. Among authors: mirabella m. J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):944-51. doi: 10.1136/jnnp-2015-312591. Epub 2016 May 9. J Neurol Neurosurg Psychiatry. 2016. PMID: 27160523 Free PMC article.
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.
Prosperini L, Saccà F, Cordioli C, Cortese A, Buttari F, Pontecorvo S, Bianco A, Ruggieri S, Haggiag S, Brescia Morra V, Capra R, Centonze D, Di Battista G, Ferraro E, Francia A, Galgani S, Gasperini C, Millefiorini E, Mirabella M, Pozzilli C. Prosperini L, et al. Among authors: mirabella m. J Neurol. 2017 Feb;264(2):284-294. doi: 10.1007/s00415-016-8343-5. Epub 2016 Nov 22. J Neurol. 2017. PMID: 27878443
292 results